Trial Profile
European patients' registry for urea cycle defects and organic acidaemias (E-IMD) and European network and registry for homocystinurias and methylation defects (E-HOD) and European post marketing registry for RAVICTI® (Glycerolphenylbutyrat), oral liquid, in cooperation with the European registry and network for intoxication type metabolic diseases – E-IMD (RRPE) - E-IMD/ EHOD/ RRPE
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Glycerol phenylbutyrate (Primary)
- Indications Inborn urea cycle disorders
- Focus Therapeutic Use
- Acronyms E-IMD/ EHOD/ RRPE
- 15 Dec 2017 New trial record